RayKnowChina Research Map
Shortlist

ZhengzhouZhengzhou University

Henan Provincial People's Hospital

河南省人民医院

Listed for 37 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Henan Provincial People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌3 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌20 papers led
  3. Hepatocellular carcinoma肝细胞癌30 papers led
  4. Stomach cancer胃癌25 papers led
  5. Lung cancer肺癌66 papers led
  6. Pancreatic cancer胰腺癌13 papers led
  7. Breast cancer乳腺癌39 papers led
  8. Glioma胶质瘤56 papers led6 open trials led
  9. Retinoblastoma视网膜母细胞瘤2 papers led
  10. Chordoma脊索瘤0 papers led
  11. Osteosarcoma骨肉瘤7 papers led
  12. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  13. Neuroblastoma神经母细胞瘤3 papers led
  14. Ewing sarcoma尤文肉瘤0 papers led
  15. Multiple myeloma多发性骨髓瘤5 papers led
  16. Lymphoma淋巴瘤13 papers led
  17. Haemophilia A血友病 A2 papers led
  18. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  19. Fanconi anaemia范可尼贫血1 paper led
  20. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病2 papers led
  21. Myasthenia gravis重症肌无力2 papers led
  22. Moyamoya disease烟雾病5 papers led
  23. Coronary heart disease冠心病26 papers led
  24. Congenital heart disease先天性心脏病14 papers led
  25. Scoliosis脊柱侧弯0 papers led
  26. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  27. Takayasu arteritis大动脉炎0 papers led
  28. Idiopathic pulmonary fibrosis特发性肺纤维化5 papers led
  29. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  30. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  31. IgA nephropathyIgA 肾病1 paper led
  32. Osteogenesis imperfecta成骨不全症0 papers led
  33. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  34. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  35. Inherited epidermolysis bullosa遗传性大疱性表皮松解症2 papers led
  36. Hereditary angioedema遗传性血管性水肿0 papers led
  37. Leber hereditary optic neuropathyLeber 遗传性视神经病变3 papers led

Not listed for: Hepatoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, IgG4-related disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Hirschsprung disease, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 3 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

4 hospitals in Zhengzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyEBV & screening
Departments in papersENT / head & neck surgeryMedical oncology
Papers it led3
  1. miR-34c-3p Inhibits Nasopharyngeal Carcinoma Development via Inhibiting M2 Polarization of Macrophages.2025Biomedical and environmental sciences : BES
  2. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.2023Frontiers in immunologyFree full text
  3. Hsa_circ_0000345 inhibits cell proliferation, migration and invasion of nasopharyngeal carcinoma cells via miR-513a-3p/PTEN axis.2022The journal of physiological sciences : JPSFree full text
All its trials on ClinicalTrials.gov, any status1
  1. Intermittent Oro-esophageal Tube Feeding in Late Dysphagia for Nasopharyngeal CarcinomaWithdrawnNCT06248879Lead sponsorN/AStart 2024-02
More papers found outside PubMed (not counted)10
  1. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  2. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  3. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  4. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  5. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  6. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  7. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  8. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  9. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  10. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 20 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
20
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 4420232024: 5520242025: 442025

6 hospitals in Zhengzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
    Phase
    Not given
    Started
    2022-07
    Posted
    Registry
    NCT05443841

    Age not stated (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 8 listed hospitals as study sitesHefei, Nantong, Shanghai, Shijiazhuang, Taizhou (Jiangsu), Tianjin, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsImmunotherapyEarly detection & endoscopy
Departments in papersMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led20
  1. Biocompatible hydrogel co-delivering salvigenin and iridium (III) complex overcomes cancer stemness and cisplatin resistance in esophageal squamous cell carcinoma.2026Colloids and surfaces. B, Biointerfaces
  2. Multi-omics analysis unveils a four-gene prognostic signature in esophageal squamous carcinoma and the therapeutic potential of PKP1.2025BMC cancerFree full text
  3. Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study.2025Frontiers in immunologyFree full text
  4. METTL3-Mediated m6A Methylation Stabilizes IFI27 to Drive Esophageal Squamous Cell Carcinoma Progression Through an IGF2BP2-Dependent Mechanism.2025Journal of biochemical and molecular toxicology
  5. Screening, Validation, and Machine Learning-Based Evaluation of Serum Protein Biomarkers for Esophageal Squamous Cell Carcinoma Based on Single-Cell Subtype-Specific Genes.2025Journal of proteome research
  6. Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula.2024Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  7. Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling.2024Cancer biology & therapyFree full text
  8. DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3.2024Journal of translational medicineFree full text
  9. EVA1B facilitates esophageal squamous carcinoma progression and recruitment of immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment.2024Pharmacological research
  10. The anti-tumor activity of tangeretin in esophageal squamous cell carcinoma by inhibiting GLI2-mediated transcription of GPNMB.2024PloS oneFree full text
  11. LincRNA-P21 knockdown facilitates esophageal squamous cell carcinoma cell progression by upregulating cadherin 5 via YTH domain containing 1.2023Acta biochimica et biophysica SinicaFree full text
  12. Exosomal circ_0026611 contributes to lymphangiogenesis by reducing PROX1 acetylation and ubiquitination in human lymphatic endothelial cells (HLECs).2023Cellular & molecular biology lettersFree full text
  13. Hsa_circ_0046534 accelerates esophageal squamous cell carcinoma proliferation and metastasis via regulating MMP2 expression by sponging miR-339-5p.2023Cellular signalling
  14. The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma.2023MedicineFree full text
  15. DNA methyltransferase 3 beta regulates promoter methylation of microRNA-149 to augment esophageal squamous cell carcinoma development through the ring finger protein 2/Wnt/β-catenin axis.2022BioengineeredFree full text
  16. HA-ADT suppresses esophageal squamous cell carcinoma progression via apoptosis promotion and autophagy inhibition.2022Experimental cell research
  17. Identification of a novel circ_0001946/miR-1290/SOX6 ceRNA network in esophageal squamous cell cancer.2022Thoracic cancerFree full text
  18. Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma.2021BMC microbiologyFree full text
  19. RELT promotes the growth of esophageal squamous cell carcinoma by activating the NF-κB pathway.2021Cell cycle (Georgetown, Tex.)Free full text
  20. TMEM161B-AS1 suppresses proliferation, invasion and glycolysis by targeting miR-23a-3p/HIF1AN signal axis in oesophageal squamous cell carcinoma.2021Journal of cellular and molecular medicineFree full text
All its trials on ClinicalTrials.gov, any status3
  1. Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)RecruitingNCT05443841Study siteStart 2022-07
  2. TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Status unknownNCT05013697Study sitePhase 2Start 2021-09
  3. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
More papers found outside PubMed (not counted)9
  1. 2119P Perioperative study of BTLA combined with PD-1 and chemotherapy as bispecific immunosuppressants for resectable thoracic esophageal squamous cell carcinoma (BT-NICE trial): A prospective, single group, phase II study2025Annals of Oncologyarticle
  2. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  3. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  4. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  5. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  6. Encouraging efficacy of sintilimab combined with nanoparticle albumin-bound paclitaxel and platinum as the first-line treatment for metastatic esophageal squamous cell carcinoma: A retrospective study.2022Journal of Clinical Oncologyconference-abstract
  7. Preliminary study on the role and mechanism of KIRREL3 in the development of esophageal squamous cell carcinoma (ESCC)2022Research Squarepreprint
  8. LRP16 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma by Regulating Hippo Signaling Pathway2021Research Squarepreprint
  9. LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling2021Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 30 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
30
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 7720212022: 7720222023: 2220232024: 3320242025: 10102025

3 hospitals in Zhengzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionHepatitis B & cirrhosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led30
  1. WTAP contributes to the malignancy and stemness of hepatocellular carcinoma through upregulating N6-methyladenosine modification of ITGB4.2026Pathology, research and practice
  2. Value of Abbreviated Magnetic Resonance Sequence in Hepatocellular Carcinoma Screening: A Systematic Review and Meta-analysis.2025Academic radiology
  3. HLA-DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T-Cell Exhaustion in HBV-Associated Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  4. Imaging-Based Prediction of Ki-67 Expression in Hepatocellular Carcinoma: A Retrospective Study.2025Cancer medicineFree full text
  5. Multi-omics spatial characteristics of CD8+TRM cells in hepatocellular carcinoma and immunotherapy response prediction.2025Frontiers in immunologyFree full text
  6. The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma.2025Frontiers in immunologyFree full text
  7. Integrated bioinformatics and in vitro validation reveal TUBB as a core gene and therapeutic target in NAFLD-related hepatocellular carcinoma.2025International journal of biological macromolecules
  8. Increased expression of DNAJC7 promotes the progression of hepatocellular carcinoma by influencing the cell cycle and immune microenvironment.2025Journal of cancer research and clinical oncologyFree full text
  9. FAIM modulates HCC progression via enhancing HMGA1 interaction with CDK7 and promoting its phosphorylation level.2025Journal of translational medicineFree full text
  10. Transcriptional regulation of tumor suppressor gene RASSF1A by HBx.2025Molecular and cellular probes
  11. OTUD7B is a new deubiquitinase targeting p53.2025TheranosticsFree full text
  12. Proteo-genomic characterization of cirrhosis-associated liver cancers reveals potential subtypes and therapeutic targets.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  13. Myocardial and Cerebral Infarction after Transarterial Bland Microsphere Embolization for Hepatocellular Carcinoma: A Case Report.2024Journal of vascular and interventional radiology : JVIR
  14. TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3.2024Scientific reportsFree full text
  15. LncRNA RP11-620J15.3 promotes HCC cell proliferation and metastasis by targeting miR-326/GPI to enhance glycolysis.2023Biology directFree full text
  16. Noninvasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma Using Machine Learning-Based Ultrasomics: A Multicenter Study.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  17. Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling.2022BioengineeredFree full text
  18. LINC01419 Promotes the Proliferation of Hepatoma Cells by Recruiting XRCC5 and Regulating Its Phosphorylation to Repair DNA Damage.2022Disease markersFree full text
  19. Hydroxyacid Oxidase 2 (HAO2) Inhibits the Tumorigenicity of Hepatocellular Carcinoma and Is Negatively Regulated by miR-615-5p.2022Journal of immunology researchFree full text
  20. LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma.2022Laboratory investigation; a journal of technical methods and pathology
  21. The long non-coding RNA LIMT inhibits metastasis of hepatocellular carcinoma and is suppressed by EGF signaling.2022Molecular biology reportsFree full text
  22. Sarcopenia as an Independent Risk Factor for Specific Cancers: A Propensity Score-Matched Asian Population-Based Cohort Study.2022NutrientsFree full text
  23. Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation.2022Pharmaceutical biologyFree full text
  24. Evaluation of Glypican-3 Expression in Hepatocellular Carcinoma by Using IDEAL IQ Magnetic Resonance Imaging.2021Academic radiology
  25. miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.2021Biochemical and biophysical research communications
  26. Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma: an integrated analysis of GEO datasets.2021BioengineeredFree full text
  27. Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data.2021British journal of cancerFree full text
  28. ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway.2021Cell cycle (Georgetown, Tex.)Free full text
  29. Hybrid network with difference degree and attention mechanism combined with radiomics (H-DARnet) for MVI prediction in HCC.2021Magnetic resonance imaging
  30. CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis.2021Scientific reportsFree full text
Chinese-language papers (not in the count)2
  1. [Circ_0026134 regulates the miR-1270/GRB2 pathway to affect the radiosensitivity of hepatoma cells].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Problems and pitfalls of the hepatocyte-specific contrast agent gadoxetate disodium for assessing the main criteria of LI-RADS version 2018].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  2. A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)Status unknownNCT06023147Study siteN/AStart 2023-09
  3. Nurse-led Decision Counseling on Hepatocellular Carcinoma ScreeningCompletedNCT04659005Study siteN/AStart 2021-02
  4. Autologous CAR-T/TCR-T Cell Immunotherapy for Solid MalignanciesStatus unknownNCT03941626Study sitePhase 1/Phase 2Start 2019-09

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 25 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
25
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 8820222023: 1120232024: 6620242025: 332025

4 hospitals in Zhengzhou for stomach cancer211 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseImaging & AI
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineMedical oncology
Papers it led25
  1. Spatial transcriptomic characteristics of gastric cancer in young and the expression and role of TMEM176B in gastric cancer cells.2025European journal of medical researchFree full text
  2. Global Prevalence of Helicobacter pylori Infection-Associated Gastric Preneoplastic Lesions in Pediatric Patients: A Systematic Review and Meta-Analysis.2025Helicobacter
  3. An interpretable hybrid deep learning framework for gastric cancer diagnosis using histopathological imaging.2025Scientific reportsFree full text
  4. The three-stage and seven-step method for laparoscopic radical gastrectomy: A new surgical procedure for gastric cancer.2024Asian journal of surgery
  5. Pathological complete remission (PCR) in a patient with unresectable gastric cancer undergoing preoperative conversion therapy.2024Asian journal of surgery
  6. Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.2024Helicobacter
  7. Benzimidazole-based structure optimization to discover novel anti-gastric cancer agents targeting ROS/MAPK pathway.2024Journal of biochemical and molecular toxicology
  8. Sensitivity and specificity of folate receptor α-positive circulating tumour cells in gastric cancer.2024Postgraduate medical journal
  9. Comprehensive analysis of risk factors associated with submucosal invasion in patients with early-stage gastric cancer.2024World journal of gastroenterologyFree full text
  10. Relationship between the number of dissected lymph node and the pathological staging in esophagogastric junction adenocarcinoma.2023Asian journal of surgery
  11. Identification of a seven-cell cycle signature predicting overall survival for gastric cancer.2022AgingFree full text
  12. Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.2022Disease markersFree full text
  13. Non-invasive measurement of tumor immune microenvironment and prediction of survival and chemotherapeutic benefits from 18F fluorodeoxyglucose PET/CT images in gastric cancer.2022Frontiers in immunologyFree full text
  14. Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.2022Helicobacter
  15. "Two-Side Approach, Four-Step Dissociation" Surgical Technique for Splenic Hilar Lymphadenectomy During Laparoscopic Total Gastrectomy for Advanced Gastric Cancer.2022Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  16. Plasma Exosomal hsa_circ_0015286 as a Potential Diagnostic and Prognostic Biomarker for Gastric Cancer.2022Pathology oncology research : PORFree full text
  17. Family-based Helicobacter pylori infection status and transmission pattern in central China, and its clinical implications for related disease prevention.2022World journal of gastroenterologyFree full text
  18. Gastric mucosal precancerous lesions in Helicobacter pylori-infected pediatric patients in central China: A single-center, retrospective investigation.2022World journal of gastroenterologyFree full text
  19. Knockdown of hsa_circ_0091994 constrains gastric cancer progression by suppressing the miR-324-5p/HMGA1 axis.2021AgingFree full text
  20. A novel circular RNA circ_HN1/miR-628-5p/Ecto-5'-nucleotidase competing endogenous RNA network regulates gastric cancer development.2021BioengineeredFree full text
  21. Tissue-based metabolomics reveals metabolic signatures and major metabolic pathways of gastric cancer with help of transcriptomic data from TCGA.2021Bioscience reportsFree full text
  22. CDC42EP3 is a key promoter involved in the development and progression of gastric cancer.2021Carcinogenesis
  23. m6 A transferase KIAA1429-stabilized LINC00958 accelerates gastric cancer aerobic glycolysis through targeting GLUT1.2021IUBMB life
  24. Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells.2021Investigational new drugs
  25. STROBE-clinical characteristics and prognosis factors of gastric cancer in young patients aged ≤30 years.2021MedicineFree full text
Chinese-language papers (not in the count)1
  1. [Application of 3D-CT simulation image in the description of gastric artery variation to guide laparoscopic total gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status6
  1. HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk PatientsStatus unknownNCT05510388Study siteN/AStart 2022-09
  2. Nasal Mask Kit in Gastrointestinal EndoscopyCompletedNCT05405530Study siteN/AStart 2022-09
  3. Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly PatientsCompletedNCT05030870Study siteN/AStart 2021-09
  4. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Study sitePhase 3Start 2020-09
  5. Autologous CAR-T/TCR-T Cell Immunotherapy for Solid MalignanciesStatus unknownNCT03941626Study sitePhase 1/Phase 2Start 2019-09
  6. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 66 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
66
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 101020212022: 9920222023: 101020232024: 171720242025: 19192025

3 hospitals in Zhengzhou for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
    Phase
    Phase 3
    Started
    2026-04
    Posted
    Registry
    NCT07416474

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai

  2. Recruiting
    A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07444437

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Zhengzhou

  3. Recruiting
    Pragmatic AI-Assisted Lung Cancer Translational Study
    Phase
    N/A
    Started
    2026-08
    Posted
    Registry
    NCT07941128

    Age 18 years to Not stated (registered criteria)

    Led by Sir Run Run Shaw Hospital; 1 listed hospital as study siteHangzhou, Zhengzhou

  4. Recruiting
    A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07217301

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou

  5. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

  6. Recruiting
    Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
    Phase
    N/A
    Started
    2024-09
    Posted
    Registry
    NCT06572540

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Shanghai, Zhengzhou

  7. Recruiting
    A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
    Phase
    Phase 1/Phase 2
    Started
    2022-10
    Posted
    Registry
    NCT07231068

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Zhengzhou

  8. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  9. Not yet recruiting
    Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
    Phase
    N/A
    Started
    2025-09
    Posted
    Registry
    NCT07135297

    Age 18 years to Not stated (registered criteria)

    Led by Shanghai Chest Hospital; 4 listed hospitals as study sitesBeijing, Nanjing, Ningbo, Shanghai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineMedical oncologyPathology / laboratory medicineNeurology
Papers it led66
  1. FBXL6 drives tumorigenesis in lung adenocarcinoma through ubiquitination and proteasomal degradation of CDKN1C.2026Experimental cell research
  2. Targeting NAD + biosynthesis suppresses TGF-β1/Smads/RAB26 axis and potentiates cisplatin cytotoxicity in non-small cell lung cancer brain metastasis.2025Acta neuropathologica communicationsFree full text
  3. Prognostic performance of the nutritional risk screening 2002 and the global leadership initiative on malnutrition in patients with lung cancer treated with immune checkpoint inhibitors.2025BMC cancerFree full text
  4. Metabolic and multi-model intravoxel incoherent motion parameters based 18F-FDG PET/MRI for predicting subtypes of inoperable non-small cell lung cancer.2025BMC cancerFree full text
  5. Identification of a Risk Signature and Immune Cell Infiltration Based on Extracellular Matrix-Related lncRNAs in Lung Adenocarcinoma.2025Critical reviews in eukaryotic gene expression
  6. Effect of Nebulized Dexmedetomidine on Postoperative Nausea and Vomiting in Female Patients Undergoing Radical Thoracoscopic Lung Cancer Resection: A Single-Center Randomized Controlled Trial.2025Drug design, development and therapyRCTFree full text
  7. Influence of diabetes mellitus on metabolic networks in lung cancer patients: an analysis using dynamic total-body PET/CT imaging.2025European journal of nuclear medicine and molecular imaging
  8. Targeting BUB1B-driven cancer stemness in lung adenocarcinoma: a novel therapeutic strategy via PI3K/AKT pathway modulation.2025Expert opinion on therapeutic targets
  9. Association between high-density lipoprotein cholesterol and 7-autoantibodies: a study on physical examination data from 2018 to 2023.2025Frontiers in endocrinologyFree full text
  10. Targeted and personalized immunotherapy in lung adenocarcinoma: single-cell RNA sequencing of MAFF+ tumor cells and the therapeutic potential of FOS.2025Frontiers in immunologyFree full text
  11. Tri-Compartmental Restriction Spectrum Imaging Based on 18F-FDG PET/MR for Identification of Primary Benign and Malignant Lung Lesions.2025Journal of magnetic resonance imaging : JMRI
  12. Assessment of Lung Nodule Detection and Lung CT Screening Reporting and Data System Classification Using Zero Echo Time Pulmonary MRI.2025Journal of magnetic resonance imaging : JMRI
  13. Multiparametric 18F-FDG PET/MRI based on restrictive spectrum imaging and amide proton transfer-weighted imaging facilitates the assessment of lymph node metastases in non-small cell lung cancer.2025La Radiologia medica
  14. Exploring the mechanism of the potential effects of Liujunzi Tang combined with Suanzaoren Tang in the treatment of lung cancer with insomnia based on network pharmacology and molecular docking technology.2025MedicineFree full text
  15. CXCR1 and CXCR2 Antagonism with G31P Attenuates Chemotherapy-Induced Lung Inflammation and Augments the Gefitinib Therapeutic Response in Lung Cancer.2025Oncology researchFree full text
  16. Feedforward control with personalized nursing measures on respiratory function and psychological status in patients with advanced lung cancer.2025Scientific reportsFree full text
  17. Shape sensing robotic assisted bronchoscopy versus virtual bronchoscopic navigation in the diagnosis of peripheral pulmonary nodules.2025Scientific reportsFree full text
  18. The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.2025The oncologistFree full text
  19. Effects of penehyclidine hydrochloride on postoperative nausea and vomiting in patients who underwent radical thoracoscopic lung cancer surgery: study protocol for a single-center, prospective, randomized controlled clinical trial.2025TrialsFree full text
  20. Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy.2025World journal of surgical oncologyFree full text
  21. Predictive value of metabolic parameters and apparent diffusion coefficient derived from 18F-FDG PET/MR in patients with non-small cell lung cancer.2024BMC medical imagingFree full text
  22. Effect of age on postoperative 24-hour moderate-to-severe pain after radical resection of lung cancer-specific pain in the post-anaesthesia care unit: a single-centre retrospective cohort study.2024BMJ openFree full text
  23. The deubiquitinating protein OTUD6B promotes lung adenocarcinoma progression by stabilizing RIPK1.2024Biology directFree full text
  24. The Correlation Between the Natural Course, Pathologic Properties With Ki-67 Expression in Lung Adenocarcinoma Presenting as Ground-Glass Nodules.2024Cancer medicineFree full text
  25. Reporting quality evaluation of clinical practice guidelines for pulmonary nodules with the RIGHT checklist.2024Chinese medical journalFree full text
  26. An [18F]FDG PET/3D-ultrashort echo time MRI-based radiomics model established by machine learning facilitates preoperative assessment of lymph node status in non-small cell lung cancer.2024European radiology
  27. CD146 Promotes EMT-Mediated Migration and Invasion of NSCLC via PI3K/Akt Signaling Pathway.2024Frontiers in bioscience (Landmark edition)
  28. Effect of multidisciplinary team-style continuity of care and nutritional nursing on lung cancer: randomized study.2024Future oncology (London, England)RCTFree full text
  29. Comprehensive analysis of single-cell transcriptomics and genetic factors reveals the mechanisms and preventive strategies for the progression from pulmonary fibrosis to lung cancer.2024International immunopharmacology
  30. Effect of preoperative natural killer cell on postoperative pulmonary complications in patients of lung cancer - A single-center retrospective cohort study.2024International immunopharmacology
  31. SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: A potential therapeutic target.2024International immunopharmacology
  32. Multiple primary lung cancer: Updates and perspectives.2024International journal of cancer
  33. Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.2024Journal of cancer research and clinical oncologyFree full text
  34. Amide Proton Transfer-Weighted Imaging and Multiple Models Intravoxel Incoherent Motion-Based 18F-FDG PET/MRI for Predicting Progression-Free Survival in Non-Small Cell Lung Cancer.2024Journal of magnetic resonance imaging : JMRI
  35. Attention pyramid pooling network for artificial diagnosis on pulmonary nodules.2024PloS oneFree full text
  36. Endobronchial Ultrasound-Based Support Vector Machine Model for Differentiating between Benign and Malignant Mediastinal and Hilar Lymph Nodes.2024Respiration; international review of thoracic diseases
  37. Advances in the Treatment of Pulmonary Nodules.2024Respiration; international review of thoracic diseases
  38. Fear of progression among postoperative patients with newly diagnosed lung cancer: a cross-sectional survey in China.2023BMC psychologyFree full text
  39. Building Awareness of Diagnosis Together: Ambiguity During Progression-Free Survival Experienced by Patients With Lung Cancer and Caregivers in China.2023Cancer nursing
  40. Comparative immunological landscape between pre- and early-stage LUAD manifested as ground-glass nodules revealed by scRNA and scTCR integrated analysis.2023Cell communication and signaling : CCSFree full text
  41. Bronchoscopic transparenchymal nodule access in the diagnosis and management of pulmonary nodules.2023Chinese medical journalFree full text
  42. Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy.2023Clinical lung cancer
  43. Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma.2023Journal of cancer research and clinical oncologyFree full text
  44. Feasibility and Safety of Endosonography-Guided Transvascular Needle Aspiration in the Diagnosis of Thoracic and Abdominal Lesions: A Meta-Analysis.2023Respiration; international review of thoracic diseases
  45. A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.2023Scientific reportsFree full text
  46. A diagnostic classification of lung nodules using multiple-scale residual network.2023Scientific reportsFree full text
  47. Transcriptome analysis reveals the differential inflammatory effects between propofol and sevoflurane during lung cancer resection: a randomized pilot study.2023World journal of surgical oncologyRCTFree full text
  48. Extrinsic emotional regulation experienced by lung cancer patients and their family caregivers during progression-free survival.2022European journal of cancer care
  49. Identifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging.2022European journal of nuclear medicine and molecular imagingFree full text
  50. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.2022Frontiers in endocrinologyFree full text
  51. Identification of Benign and Malignant Lung Nodules in CT Images Based on Ensemble Learning Method.2022Interdisciplinary sciences, computational life sciences
  52. Application of Simultaneous 18 F-FDG PET With Monoexponential, Biexponential, and Stretched Exponential Model-Based Diffusion-Weighted MR Imaging in Assessing the Proliferation Status of Lung Adenocarcinoma.2022Journal of magnetic resonance imaging : JMRI
  53. Evaluation of Amide Proton Transfer-Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters.2022Journal of magnetic resonance imaging : JMRI
  54. Application of rapid rehabilitation surgical concept in perioperative nursing of patients undergoing single-port thoracoscopic lobectomy.2022Minerva medica
  55. Effects of serratus anterior plane block and thoracic paravertebral nerve block on analgesia, immune function and serum tumor markers in patients after thoracoscopic radical resection of lung cancer.2022Nagoya journal of medical scienceRCTFree full text
  56. Diagnostic value of LungPoint navigation combined with EBUS-GS & ROSE in peripheral pulmonary nodules.2022The Indian journal of medical researchFree full text
  57. Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway.2021Biological researchFree full text
  58. Angio-associated migratory cell protein (AAMP) interacts with cell division cycle 42 (CDC42) and enhances migration and invasion in human non-small cell lung cancer cells.2021Cancer letters
  59. LncRNA GAS6-AS2 promotes non-small-cell lung cancer cell proliferation via regulating miR-144-3p/ MAPK6 axis.2021Cell cycle (Georgetown, Tex.)Free full text
  60. Risk assessment of malignancy in solitary pulmonary nodules in lung computed tomography: a multivariable predictive model study.2021Chinese medical journalFree full text
  61. Clinical and functional significance of a novel ferroptosis-related prognosis signature in lung adenocarcinoma.2021Clinical and translational medicineFree full text
  62. Total-body dynamic PET/CT of micro-metastatic lymph node in a patient with lung cancer.2021European journal of nuclear medicine and molecular imaging
  63. Natural killer cell exhaustion in lung cancer.2021International immunopharmacology
  64. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.2021Life sciences
  65. Circ_0089823 reinforces malignant behaviors of non-small cell lung cancer by acting as a sponge for microRNAs targeting SOX4.2021Neoplasia (New York, N.Y.)Free full text
  66. Propofol suppresses lung cancer tumorigenesis by modulating the circ-ERBB2/miR-7-5p/FOXM1 axis.2021Thoracic cancerFree full text
Chinese-language papers (not in the count)8
  1. [Male non gestational choriocarcinoma with widespread systemic metastasis: report of two cases].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [circDDX17 targets miR-223-3p / RIP3 to regulate the proliferation and apoptosis of non-small cell lung cancer cells].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
  3. [Primary synovial sarcoma of lung: a clinicopathological analysis of 12 cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Clinicopathological features of lung adenocarcinoma with mesothelioma like growth pattern: report of three cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [Clinical characteristics of anti-CV2 antibody-associated neurological diseases].2021Zhonghua yi xue za zhi
  6. [Clinical features and prognosis of patients with leptomeningeal metastases].2021Zhonghua yi xue za zhi
  7. [The influence of cachexia on the immunotherapy efficacy of Sintilimab for non-small cell lung cancer].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
  8. [Triptolide increases the radiosensitivity of lung cancer cells by inhibiting DNA repair and inducing apoptosis].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status25
  1. Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLCStatus unknownNCT03778138Lead sponsorPhase 2Start 2019-01
  2. Conmana Combined With Thalidomide to Treat NSCLCStatus unknownNCT02778893Lead sponsorPhase 4Start 2016-03
  3. A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung CancerRecruitingNCT07444437Study sitePhase 2Start 2026-02
  4. RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT07416474Study sitePhase 3Start 2026-04
  5. Pragmatic AI-Assisted Lung Cancer Translational StudyRecruitingNCT07941128Study siteN/AStart 2026-08
  6. A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerRecruitingNCT07217301Study sitePhase 3Start 2025-11
  7. Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary NodulesNot yet recruitingNCT07135297Study siteN/AStart 2025-09
  8. Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung CancerRecruitingNCT06572540Study siteN/AStart 2024-09
  9. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Study sitePhase 3Start 2024-03
  10. A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR MutationRecruitingNCT07231068Study sitePhase 1/Phase 2Start 2022-10
  11. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Study sitePhase 1/Phase 2Start 2021-09
  12. Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung CancerTerminatedNCT06897579Study sitePhase 2Start 2025-04
  13. A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk FactorsStatus unknownNCT06143735Study sitePhase 2Start 2023-12
  14. IN10018 Combination Therapy in Treatment-naïve ES-SCLCActive, not recruitingNCT06030258Study sitePhase 1/Phase 2Start 2023-10
  15. Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLCActive, not recruitingNCT05092412Study sitePhase 2Start 2022-03
  16. HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyActive, not recruitingNCT05338970Study sitePhase 3Start 2022-07
  17. A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerActive, not recruitingNCT05297890Study sitePhase 2Start 2022-05
  18. A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in ChinaCompletedNCT04830826Study siteStart 2020-07
  19. Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Study sitePhase 3Start 2020-09
  20. Early Cancer Detection Test - Lung Cancer ChinaStatus unknownNCT04216511Study siteStart 2019-08
  21. A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC PatientsCompletedNCT04001777Study sitePhase 1Start 2019-07
  22. Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT03972189Study sitePhase 2Start 2019-07
  23. A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCStatus unknownNCT03668496Study sitePhase 3Start 2018-11
  24. Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)CompletedNCT02973789Study sitePhase 3Start 2016-12
  25. Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in ChinaCompletedNCT01928836Study siteStart 2012-10

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 13 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 4420232024: 0020242025: 442025

3 hospitals in Zhengzhou for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
    Phase
    Not given
    Started
    2024-04
    Posted
    Registry
    NCT06375473

    Age 18 years to 100 years (registered criteria)

    Led by Peking Union Medical College Hospital; 7 listed hospitals as study sitesBeijing, Hefei, Nanning, Ningbo, Shanghai, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led13
  1. Astragaloside IV promotes the apoptosis of pancreatic cancer cells by activating endoplasmic reticulum stress through the PERK/ATF4/CHOP signaling pathway.2026Molecular medicine reportsFree full text
  2. Comprehensive bioinformatics analysis of the prognostic value and immune infiltration of CAPN2 in pancreatic adenocarcinoma.2025Gene
  3. SPP1 + macrophages facilitate pancreatic cancer progression via ITGB6-mediated interactions: evidence from integrated multi-omics analysis and experimental validation.2025Immunologic research
  4. Multi-omics integration and machine learning uncover molecular basal-like subtype of pancreatic cancer and implicate A2ML1 in promoting tumor epithelial-mesenchymal transition.2025Journal of translational medicineFree full text
  5. PLK1 inhibition enhances gemcitabine-induced apoptosis through PLK1-dependent ERK1/2-Bim and AKT1/Noxa signals in pancreatic cancer cells.2025Medical oncology (Northwood, London, England)Free full text
  6. Immortalization-upregulated protein promotes pancreatic cancer progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint protein activity.2023Cell biology and toxicologyFree full text
  7. Identification of a potential prognostic model combining pyroptosis-related gene with immune microenvironment for pancreatic ductal adenocarcinoma.2023Journal of cancer research and clinical oncologyFree full text
  8. Integrin αvβ3 and EGFR dual-targeted [64Cu]Cu-NOTA-RGD-GE11 heterodimer for PET imaging in pancreatic cancer mouse model.2023Nuclear medicine and biology
  9. A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.2023Scientific reportsFree full text
  10. The clinical significance of circulating tumor cells and T lymphocyte subtypes in pancreatic cancer patients.2022BioengineeredFree full text
  11. Identifying cancer cell-secreted proteins that activate cancer-associated fibroblasts as prognostic factors for patients with pancreatic cancer.2022Journal of cellular and molecular medicineFree full text
  12. Clinical features and prognostic factors of elderly patients with metastatic pancreatic cancer: a population-based study.2021AgingFree full text
  13. Predictive significance of tumor budding in postoperative liver metastasis of pancreatic neuroendocrine tumors.2021Journal of surgical oncology
All its trials on ClinicalTrials.gov, any status2
  1. Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer PatientsRecruitingNCT06375473Study siteStart 2024-04
  2. Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)CompletedNCT03377491Study sitePhase 3Start 2018-05

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 39 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
39
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 141420212022: 6620222023: 4420232024: 7720242025: 772025

3 hospitals in Zhengzhou for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    SMP-656 for HER2-Positive Advanced Breast Cancer
    Phase
    Phase 2
    Started
    2026-08
    Posted
    Registry
    NCT07726342

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou

  2. Recruiting
    A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Phase
    Phase 2/Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06891833

    Age 18 years to 75 years; women only (registered criteria)

    Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  3. Recruiting
    A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
    Phase
    Not given
    Started
    2024-01
    Posted
    Registry
    NCT06210776

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai

  4. Recruiting
    Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
    Phase
    Phase 4
    Started
    2021-06
    Posted
    Registry
    NCT04790305

    Age 18 years to 70 years (registered criteria)

    Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineMedical oncologySurgery (general/hepatobiliary/pancreatic)
Papers it led39
  1. ATM promotes bone metastatic propensity of breast cancer by inducing osteoclastogenesis via the NFκB-CCL2 pathway.2026Acta pharmacologica Sinica
  2. Identification of risk factors and development of predictive models for chronic postsurgical pain after modified radical mastectomy.2025Annals of medicineFree full text
  3. Predictive value of shear wave elastography and molecular subtypes for postoperative efficacy in patients with early breast cancer.2025Annals of medicineFree full text
  4. The chain mediating effects of psychological resilience and family support on the association between taste alteration and cancer anorexia among Chinese breast cancer patients undergoing chemotherapy: a cross-sectional study.2025BMC psychologyFree full text
  5. FATE1: A cancer testis antigen with oncogenic functions - Prognostic biomarker and JAK2/STAT1-driven autophagy regulator in breast cancer.2025Biochemical and biophysical research communications
  6. FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome.2025International journal of biological sciencesFree full text
  7. Spinal Metastasis Pain Surveillance: A Comprehensive Imaging-Based Tool Design for Evaluating Metastatic Burden and Guiding Therapeutic Strategies.2025International journal of medical sciencesFree full text
  8. Appraising histone H4 lysine 5 lactylation as a novel biomarker in breast cancer.2025Scientific reportsFree full text
  9. 18F-Radiolabeling and Evaluation of an AMD3465 Derivative for PET Imaging of CXCR4 in a Mouse Breast Tumor Model.2024Bioconjugate chemistry
  10. Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy.2024Breast (Edinburgh, Scotland)Free full text
  11. Development and Validation of a Nomogram for Predicting Breast Malignancy in Male Patients Based on Clinical and Ultrasound Features.2024Current radiopharmaceuticals
  12. Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer.2024OncogeneFree full text
  13. Preoperative Radiotherapy Does Not Change the Existing Treatment Paradigm in Stage III Breast Cancer.2024Oncology
  14. LINC-PINT suppresses breast cancer cell proliferation and migration via MEIS2/PPP3CC/NF-κB pathway by sponging miR-576-5p.2024The American journal of the medical sciences
  15. Excessive glutathione intake contributes to chemotherapy resistance in breast cancer: a propensity score matching analysis.2024World journal of surgical oncologyFree full text
  16. Brain metastasis in de novo stage IV breast cancer.2023Breast (Edinburgh, Scotland)Free full text
  17. Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study.2023Cancer control : journal of the Moffitt Cancer CenterFree full text
  18. Oxygen-independent alkyl radical nanogenerator enhances breast cancer therapy.2023Nanomedicine : nanotechnology, biology, and medicine
  19. A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.2023Scientific reportsFree full text
  20. Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.2022Annals of surgical oncology
  21. KDM3B-ETF1 fusion gene downregulates LMO2 via the WNT/β-catenin signaling pathway, promoting metastasis of invasive ductal carcinoma.2022Cancer gene therapy
  22. Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2.2022Cell death & diseaseFree full text
  23. HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study.2022Frontiers in endocrinologyFree full text
  24. LncRNA CASC15 regulates breast cancer cell stemness via the miR-654-5p/MEF2D axis.2022Journal of biochemical and molecular toxicology
  25. Adjuvant postmastectomy radiotherapy might be associated with better survival in women with heart failure receiving total mastectomy.2022Radiation oncology (London, England)Free full text
  26. Radiomics Signatures Based on Multiparametric MRI for the Preoperative Prediction of the HER2 Status of Patients with Breast Cancer.2021Academic radiology
  27. Polymorphisms in lncRNA MIR2052HG and susceptibility to breast cancer in Chinese population.2021AgingFree full text
  28. Removal of palpable lymph nodes during sentinel lymph node biopsy in breast cancer: Our experience.2021Asian journal of surgery
  29. Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1-2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts.2021BMC cancerFree full text
  30. FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.2021Biochimica et biophysica acta. Molecular cell research
  31. Identification of a prognostic chemoresistance-related gene signature associated with immune microenvironment in breast cancer.2021BioengineeredFree full text
  32. Paravertebral block in regional anesthesia with propofol sedation reduces locoregional recurrence in patients with breast cancer receiving breast conservative surgery compared with volatile inhalational without propofol in general anesthesi2021Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  33. FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.2021CellsFree full text
  34. Preparation and evaluation of ultrasound-mediated dual-targeted theragnostic systems utilising phase-changeable polymeric nanodroplets on the integrin αν β3 overexpressed breast cancer.2021Clinical and translational medicineFree full text
  35. A comparative study of the value of amide proton transfer-weighted imaging and diffusion kurtosis imaging in the diagnosis and evaluation of breast cancer.2021European radiology
  36. Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity.2021JAMA network openFree full text
  37. Long non-coding RNA ROR recruits histone transmethylase MLL1 to up-regulate TIMP3 expression and promote breast cancer progression.2021Journal of translational medicineFree full text
  38. SAP-cGAN: Adversarial learning for breast mass segmentation in digital mammogram based on superpixel average pooling.2021Medical physics
  39. Pathologic response rates for breast cancer stages as a predictor of outcomes in patients receiving neoadjuvant chemotherapy followed by breast-conserving surgery.2021Surgical oncology
Chinese-language papers (not in the count)1
  1. [Prospective comparative study of breast reconstruction with dual plane prosthesis implantation and anterior pectoralis prosthesis implantation under endoscopy].2024Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgeryFree full text
All its trials on ClinicalTrials.gov, any status10
  1. SMP-656 for HER2-Positive Advanced Breast CancerRecruitingNCT07726342Study sitePhase 2Start 2026-08
  2. A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Study sitePhase 2/Phase 3Start 2025-06
  3. A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)RecruitingNCT06210776Study siteStart 2024-01
  4. Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast CancerRecruitingNCT04790305Study sitePhase 4Start 2021-06
  5. A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.Status unknownNCT05845138Study sitePhase 1/Phase 2Start 2023-07
  6. FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast CancerStatus unknownNCT05755048Study sitePhase 3Start 2023-03
  7. A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerActive, not recruitingNCT05346224Study sitePhase 3Start 2022-04
  8. A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast CancerTerminatedNCT04927481Study sitePhase 2Start 2021-06
  9. Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic TreatmentCompletedNCT04085276Study sitePhase 3Start 2018-12
  10. Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In ChinaCompletedNCT01176916Study sitePhase 4Start 2011-02

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 56 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.8%.

Papers led
56
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 9920212022: 171720222023: 101020232024: 7720242025: 10102025

6 hospitals in Zhengzhou for glioma187 hospitals in China for glioma

Open trials with this hospital 6

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05512351

    Age 18 years to Not stated (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  2. Not yet recruiting
    Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
    Phase
    Phase 2
    Started
    2023-10
    Posted
    Registry
    NCT05540275

    Age 18 years to Not stated (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  3. Not yet recruiting
    Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
    Phase
    Phase 2
    Started
    2022-12
    Posted
    Registry
    NCT05502991

    Age 18 years to Not stated (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  4. Not yet recruiting
    Study on Gene Evolution in Glioma Under Stress Therapy
    Phase
    Not given
    Started
    2022-12
    Posted
    Registry
    NCT05512325

    Age 18 years to 75 years (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  5. Not yet recruiting
    Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma
    Phase
    Not given
    Started
    2022-12
    Posted
    Registry
    NCT05532969

    Age 18 years to 75 years (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

  6. Not yet recruiting
    Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
    Phase
    Not given
    Started
    2022-12
    Posted
    Registry
    NCT05541042

    Age 18 years to Not stated (registered criteria)

    Led by Henan Provincial People's HospitalZhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurosurgeryRadiology / nuclear medicineMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led56
  1. Integrated single-cell and spatial transcriptomics uncover the prognostic, epigenetic, and immunological roles of FANCC in low-grade glioma.2026Neurological research
  2. FAM111B as a biomarker influences the prognosis and immune microenvironment of low-grade gliomas.2026Neurological research
  3. PSMC3IP as a prognostic biomarker and immunomodulatory regulator in low-grade glioma: insights from multi-omics and methylation analysis.2026Neurological research
  4. Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas.2025Annals of clinical and translational neurologyFree full text
  5. POLD3 knockdown effects on low-grade glioma: insights from bioinformatics and experimental validation.2025BMC cancerFree full text
  6. Causal Association Between Immune Cell Traits and Risk of Multiple Malignant and Nonmalignant CNS Diseases: A Mendelian Randomization and Single-Cell Transcriptomic Analysis.2025Brain and behaviorFree full text
  7. Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study.2025Cancer medicineFree full text
  8. Development of a web-based tool for estimating individualized survival curves in glioblastoma using clinical, mRNA, and tumor microenvironment features with fusion techniques.2025Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  9. The oncogenic role of CCDC34 in lower-grade gliomas: prognostic significance and therapeutic potential.2025Journal of neuro-oncologyFree full text
  10. Sulforaphane-cysteine inhibits α-tubulin/PD-L1/PFKFB4 axis leading to apoptosis in human glioblastoma.2025Medical oncology (Northwood, London, England)
  11. HERC5/ISG15 Enhances Glioblastoma Stemness and Tumor Progression by mediating SERBP1protein stability.2025Neuromolecular medicine
  12. Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas.2025NeurosurgeryFree full text
  13. Zinc finger protein 800 (ZNF800) promotes proliferation and migration of lower-grade glioma and is associated with immune infiltration.2025PloS oneFree full text
  14. DSN1 may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy.2024Cancer biology & therapyFree full text
  15. Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  16. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.2024Cancer immunology, immunotherapy : CIIFree full text
  17. WD repeat domain 76 predicts poor prognosis in lower grade glioma and provides an original target for immunotherapy.2024European journal of medical researchFree full text
  18. TME-Activated MnO2/Pt Nanoplatform of Hydroxyl Radical and Oxygen Generation to Synergistically Promote Radiotherapy and MR Imaging of Glioblastoma.2024International journal of nanomedicineFree full text
  19. Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.2024Journal of cancer research and clinical oncologyFree full text
  20. Synthesis of gadolinium-enhanced glioma images on multisequence magnetic resonance images using contrastive learning.2024Medical physics
  21. LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.2023BMC cancerFree full text
  22. Genomic alterations of oligodendrogliomas at distant recurrence.2023Cancer medicineFree full text
  23. Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.2023Cellular and molecular neurobiologyFree full text
  24. Fear stress promotes glioma progression through inhibition of ferroptosis by enhancing FSP1 stability.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  25. PSRC1 Regulated by DNA Methylation Is a Novel Target for LGG Immunotherapy.2023Journal of molecular neuroscience : MN
  26. RFX2 promotes tumor cell stemness through epigenetic regulation of PAF1 in spinal ependymoma.2023Journal of neuro-oncology
  27. Caspase-3 in glioma indicates an unfavorable prognosis by involving surrounding angiogenesis and tumor cell repopulation.2023Journal of neuro-oncology
  28. Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma.2023Technology and health care : official journal of the European Society for Engineering and MedicineRCT
  29. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.2023The international journal of biochemistry & cell biology
  30. IKBKE regulates angiogenesis by modulating VEGF expression and secretion in glioblastoma.2023Tissue & cell
  31. Berberine inhibits glioma cell migration and invasion by suppressing TGF-β1/COL11A1 pathway.2022Biochemical and biophysical research communications
  32. TGIF1 overexpression promotes glioma progression and worsens patient prognosis.2022Cancer medicineFree full text
  33. High expression of HOXA4 in patients with glioma indicates unfavorable clinical outcomes.2022Cell cycle (Georgetown, Tex.)Free full text
  34. Silencing IKBKE inhibits the migration and invasion of glioblastoma by promoting Snail1 degradation.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  35. Real-time longitudinal analysis of human gliomas reveals in vivo genome evolution and therapeutic impact under standardized treatment.2022Clinical and translational medicineFree full text
  36. CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.2022Current research in translational medicine
  37. Aberrantly high DEPDC1B expression leads to poor prognosis in patients with lower-grade gliomas.2022European review for medical and pharmacological sciences
  38. Identification of PYGL as a key prognostic gene of glioma by integrated bioinformatics analysis.2022Future oncology (London, England)
  39. MiR-222-3p inhibits formation of medulloblastoma stem-like cells by targeting Notch2/c-myc signaling pathway.2022Immunopharmacology and immunotoxicology
  40. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.2022International immunopharmacology
  41. ITGB3BP is a potential biomarker associated with poor prognosis of glioma.2022Journal of cellular and molecular medicineFree full text
  42. Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.2022Journal of immunology researchFree full text
  43. DRAXIN as a Novel Diagnostic Marker to Predict the Poor Prognosis of Glioma Patients.2022Journal of molecular neuroscience : MNFree full text
  44. Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.2022MedicineFree full text
  45. Post-traumatic brain injury glioma: Characteristics, report of 2 cases report and literature review.2022MedicineFree full text
  46. A lightweight 3D UNet model for glioma grading.2022Physics in medicine and biology
  47. Long noncoding RNA SNHG9 facilitates growth of glioma stem-like cells via miR-326/SOX9 axis.2022The journal of gene medicine
  48. LINC02381 contributes to cell proliferation and hinders cell apoptosis in glioma by transcriptionally enhancing CBX5.2021Brain research bulletin
  49. Significantly high expression of NUP37 leads to poor prognosis of glioma patients by promoting the proliferation of glioma cells.2021Cancer medicineFree full text
  50. Circ-UBAP2 functions as sponges of miR-1205 and miR-382 to promote glioma progression by modulating STC1 expression.2021Cancer medicineFree full text
  51. Genome-wide CRISPR/Cas9 screening identifies CARHSP1 responsible for radiation resistance in glioblastoma.2021Cell death & diseaseFree full text
  52. Integrating real-time in vivo tumour genomes for longitudinal analysis and management of glioma recurrence.2021Clinical and translational medicineFree full text
  53. MYC/NBS1-Mediated DNA Damage Response is Involved in the Inhibitory Effect of Hydroxysafflor Yellow A on Glioma Cells.2021Drug design, development and therapyFree full text
  54. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.2021International journal of oncologyFree full text
  55. Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients.2021Molecular medicine (Cambridge, Mass.)Free full text
  56. Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients.2021Molecular medicine (Cambridge, Mass.)Free full text
All its trials on ClinicalTrials.gov, any status9
  1. Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent GlioblastomaNot yet recruitingNCT05540275Lead sponsorPhase 2Start 2023-10
  2. Study on Gene Evolution in Glioma Under Stress TherapyNot yet recruitingNCT05512325Lead sponsorStart 2022-12
  3. Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse GlioblastomaNot yet recruitingNCT05502991Lead sponsorPhase 2Start 2022-12
  4. Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary GliomaNot yet recruitingNCT05532969Lead sponsorStart 2022-12
  5. Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse OligodendrogliomaRecruitingNCT05512351Lead sponsorPhase 2Start 2022-12
  6. Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic BiomarkersNot yet recruitingNCT05541042Lead sponsorStart 2022-12
  7. Personalized Trial in ctDNA-level-relapse GlioblastomaStatus unknownNCT05539339Lead sponsorN/AStart 2022-12
  8. Correlation Between Psychological Stress and Disease Progression in Newly Diagnosed Glioblastoma PatientsStatus unknownNCT05515133Lead sponsorStart 2022-12
  9. Autologous CAR-T/TCR-T Cell Immunotherapy for Solid MalignanciesStatus unknownNCT03941626Study sitePhase 1/Phase 2Start 2019-09

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Zhengzhou for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Zhengzhou for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Chondromucinous tumors involving craniocerebral slope area: a clinicopathological analysis of eight cases].2019Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 7 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 2220232024: 1120242025: 222025

8 hospitals in Zhengzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led7
  1. Integrating single-cell transcriptomics, molecular docking, and dynamics simulations to characterize protein kinase X-linked mechanisms in osteosarcoma.2025International journal of biological macromolecules
  2. Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma.2025Scientific reportsFree full text
  3. Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.2024Orthopaedic surgeryFree full text
  4. DNMT1 determines osteosarcoma cell resistance to apoptosis by associatively modulating DNA and mRNA cytosine-5 methylation.2023FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  5. Multiproperty Polyethylenimine-Caged Platinum Nanoclusters Promote Apoptosis of Osteosarcoma Cells via Regulating the BAX-Bcl-2/Caspase-3/PARP Axis.2023Molecular pharmaceutics
  6. Circular RNA circVRK1 suppresses the proliferation, migration and invasion of osteosarcoma cells by regulating zinc finger protein ZNF652 expression via microRNA miR-337-3p.2021BioengineeredFree full text
  7. Circ-XPR1 promotes osteosarcoma proliferation through regulating the miR-214-5p/DDX5 axis.2021Human cell
Chinese-language papers (not in the count)1
  1. [The expression of neuraminidase-1 in Ewing sarcoma and its impact on sarcoma cell proliferation and migration].2023Zhonghua yi xue za zhi
Earlier papers (2016–2020)7
  1. Comprehensive Characterization of Prognostic Long Noncoding RNAs in Osteosarcoma.2020BioMed research international
  2. MicroRNA-765 targets MTUS1 to promote the progression of osteosarcoma via mediating ERK/EMT pathway.2019European review for medical and pharmacological sciences
  3. miR‑9 depletion suppresses the proliferation of osteosarcoma cells by targeting p16.2019International journal of oncology
  4. G-protein-coupled estrogen receptor suppresses the migration of osteosarcoma cells via post-translational regulation of Snail.2019Journal of cancer research and clinical oncology
  5. LncRNA SNHG15 contributes to proliferation, invasion and autophagy in osteosarcoma cells by sponging miR-141.2017Journal of biomedical science
  6. MicroRNA-139 inhibits the proliferation and migration of osteosarcoma cells via targeting forkhead-box P2.2017Life sciences
  7. Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.2016Cancer investigation

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Zhengzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. Mutation of the KIT Gene, excluding Exon 11, in Gastrointestinal Stromal Tumors.2020Biomedical and environmental sciences : BES
  2. Analyzing the molecular mechanism of the tissue specificity of gastrointestinal stromal tumors by using bioinformatics approaches.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 3 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

6 hospitals in Zhengzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPediatrics
Papers it led3
  1. miRNA326-5p Targets DKC1 Gene to Regulate Apoptosis-Related Proteins and Intervene in the Development of Neuroblastoma.2023Analytical cellular pathology (Amsterdam)Free full text
  2. The N-Myc-responsive lncRNA MILIP promotes DNA double-strand break repair through non-homologous end joining.2022Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  3. SOX17 inhibits proliferation and invasion of neuroblastoma through CXCL12/CXCR4 signaling axis.2021Cellular signalling
Chinese-language papers (not in the count)1
  1. [PTX3 promotes proliferation, invasion and drug resistance of neuroblastoma cells in children by regulating TLR4/NF-κB signaling pathway].2021Zhonghua zhong liu za zhi [Chinese journal of oncology]
Earlier papers (2016–2020)5
  1. SNHG16 Silencing Inhibits Neuroblastoma Progression by Downregulating HOXA7 via Sponging miR-128-3p.2020Neurochemical research
  2. FGF represses metastasis of neuroblastoma regulated by MYCN and TGF-β1 induced LMO1 via control of let-7 expression.2019Brain research
  3. [PDCD4 enhances the inhibitory effect of As(2)O(3) on the growth and NF-κB signaling pathway in neuroblastoma cells].2019Zhonghua zhong liu za zhi [Chinese journal of oncology]
  4. [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].2019Zhonghua zhong liu za zhi [Chinese journal of oncology]
  5. PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.2018BMC cancer

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Zhengzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Chinese-language papers (not in the count)1
  1. [The expression of neuraminidase-1 in Ewing sarcoma and its impact on sarcoma cell proliferation and migration].2023Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's SarcomaCompletedNCT05046314Study sitePhase 2Start 2024-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 0020242025: 222025

4 hospitals in Zhengzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Posted
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  2. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskRelapse & resistanceCAR-T & cell therapy
Papers it led5
  1. Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy.2025Frontiers in immunologyFree full text
  2. Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms.2025Seminars in diagnostic pathology
  3. High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.2023Discovery medicine
  4. Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.2023Leukemia & lymphoma
  5. Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era.2021MedicineFree full text
Chinese-language papers (not in the count)4
  1. [The Value of sFLC and Serum Calcium in the Diagnosis and Prognosis of Multiple Myeloma Patients].2024Zhongguo shi yan xue ye xue za zhi
  2. [Analysis of clinical and prognostic characteristics of newly diagnosed multiple myeloma with myelofibrosis patients].2024Zhonghua yi xue za zhi
  3. [The significance of bone marrow immature plasma cell burden in the prognosis of newly diagnosed multiple myeloma patients].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Clinical and biological characteristics and prognosis of patients with biclonal multiple myeloma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  3. A Study of NINLARO® in Chinese Adults With Multiple MyelomaActive, not recruitingNCT05013190Study siteStart 2021-10
  4. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 13 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
9
led by another institution
Papers led per year
2021: 5520212022: 0020222023: 0020232024: 2220242025: 662025

4 hospitals in Zhengzhou for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07496229

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengdu, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Taiyuan, Wenzhou, Wuhan, Zhengzhou

  2. Recruiting
    A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07082686

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  3. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  4. Recruiting
    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06363994

    Age 60 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  5. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  6. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06566586

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  7. Recruiting
    Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06082102

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou

  8. Not yet recruiting
    A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07784101

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  9. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersPathology / laboratory medicineRadiology / nuclear medicineNeurosurgery
Papers it led13
  1. Identification of the IFN-γ/IL-4 ratio as a prognostic biomarker and development of an immune-related prognostic model in diffuse large B-cell lymphoma.2025BMC cancerFree full text
  2. New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma.2025Frontiers in immunologyFree full text
  3. Comparative global burden analysis of lymphoma subtypes: a statistical evaluation of severity across global regions.2025Frontiers in public healthFree full text
  4. Ferroptosis-related gene analysis revealing novel biomarkers and therapeutic targets in diffuse large B-cell lymphoma.2025Scientific reportsFree full text
  5. ITK overexpression enhances T cell cytotoxicity against DLBCL through the TCR-Ca2+-Calcineurin-NFAT-IFN-γ pathway.2025Scientific reportsFree full text
  6. Clinical Potential of Copy Number Aberration as a Diagnostic and Prognostic Biomarker in Lymphoma.2025Technology in cancer research & treatmentFree full text
  7. Prognostic Value of 18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma.2024Korean journal of radiologyFree full text
  8. Comparison between Endobronchial Ultrasound-Guided Transbronchial Node Biopsy and Transbronchial Needle Aspiration: A Meta-Analysis.2024Respiration; international review of thoracic diseases
  9. NRF1-regulated CircNSUN2 promotes lymphoma progression through activating Wnt signaling pathway via stabilizing HMGA1.2021Cell cycle (Georgetown, Tex.)Free full text
  10. Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.2021European review for medical and pharmacological sciences
  11. G protein nucleolar 3 promotes Non-Hodgkin lymphoma progression by activating the Wnt/β-catenin signaling pathway.2021Experimental cell research
  12. MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma.2021HaematologicaFree full text
  13. Self-efficacy, psychological distress, and marital quality in young and middle-aged couples facing lymphoma: The mediating effect of dyadic coping.2021Psycho-oncology
Chinese-language papers (not in the count)6
  1. [Primary adrenal NK/T cell lymphoma: a clinicopathologic analysis of six cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Clinicopathological features of mature T/NK cell lymphoma with aberrant CD20 or CD79α expression].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  4. [Extranodal nasal type natural killer/T-cell lymphoma of the digestive system: a clinicopathological study of thirteen cases].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
  5. [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  6. [Efficacy and safety of PD-1 inhibitor combined with chemotherapy in the primary treatment of phase Ⅲ/Ⅳ extranodal nasal-type natural killer/T cell lymphoma].2021Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status18
  1. Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)RecruitingNCT07496229Study sitePhase 1/Phase 2Start 2026-04
  2. Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone LymphomaNot yet recruitingNCT07896590Study sitePhase 3Start 2026-10
  3. A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).Not yet recruitingNCT07784101Study sitePhase 3Start 2026-10
  4. A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)RecruitingNCT07082686Study sitePhase 2Start 2025-08
  5. A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingNCT07189065Study sitePhase 2Start 2025-11
  6. ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)RecruitingNCT06378138Study sitePhase 2/Phase 3Start 2024-05
  7. A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell LymphomaRecruitingNCT06566586Study sitePhase 2Start 2024-11
  8. A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCLRecruitingNCT06363994Study sitePhase 3Start 2024-05
  9. Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06082102Study sitePhase 3Start 2023-12
  10. A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsActive, not recruitingNCT06970743Study sitePhase 3Start 2025-05
  11. A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell LymphomaActive, not recruitingNCT05716087Study sitePhase 2Start 2023-02
  12. A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT04965493Study sitePhase 3Start 2021-09
  13. Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaCompletedNCT04849351Study sitePhase 2Start 2021-04
  14. A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Active, not recruitingNCT04224493Study sitePhase 3Start 2020-06
  15. A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)Status unknownNCT04324879Study sitePhase 2Start 2020-05
  16. A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)CompletedNCT03797456Study sitePhase 2Start 2019-04
  17. Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell LymphomaTerminatedNCT04002622Study sitePhase 2Start 2019-08
  18. A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)CompletedNCT03494179Study sitePhase 1/Phase 2Start 2018-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 2 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

5 hospitals in Zhengzhou for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led2
  1. The prediction of haemophilic arthropathy progression based on MRI findings and clinical characteristics.2025Orphanet journal of rare diseasesFree full text
  2. Acquired Hemophilia A: A Retrospective Multicenter Analysis of 42 Patients.2023Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisFree full text
Earlier papers (2016–2020)4
  1. Multislice spiral computed tomography imaging in evaluating hemophilic arthropathy.2020Chinese medical journal
  2. [Clinical study on factor Ⅷ inhibitor in children with hemophilia A].2020Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  3. Using synovial volume measurement by MRI to evaluate the effect of 32P Radiation synovectomy on hemophilic arthropathy patients.2019Journal of X-ray science and technology
  4. [Therapeutic response of radiosynovectomy with p-32 colloid in 326 patients with hemophilic arthropathy].2017Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
All its trials on ClinicalTrials.gov, any status7
  1. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  2. Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With InhibitorStatus unknownNCT05487976Study sitePhase 3Start 2022-04
  3. Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia ACompletedNCT04845399Study sitePhase 3Start 2021-04
  4. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.CompletedNCT04456387Study sitePhase 3Start 2020-10
  5. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.Status unknownNCT04061109Study sitePhase 3Start 2019-05
  6. PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia ACompletedNCT02492984Study sitePhase 4Start 2015-04
  7. Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia ACompletedNCT02634723Study siteStart 2015-12

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Zhengzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Zhengzhou for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 2 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Zhengzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Posted
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosis
Departments in papersNeurology
Papers it led2
  1. Single-cell RNA sequencing reveals cell type-specific immune regulation associated with human neuromyelitis optica spectrum disorder.2024Frontiers in immunologyFree full text
  2. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyFree full text
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

3 hospitals in Zhengzhou for myasthenia gravis89 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Posted
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesBiologic & complement drugsStandard immunotherapy
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 5 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 0020232024: 0020242025: 222025

2 hospitals in Zhengzhou for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Posted
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGeneticsRevascularisation surgeryImaging & blood flow
Departments in papersNeurosurgeryNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 26 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.5%.

Papers led
26
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 5520212022: 5520222023: 7720232024: 3320242025: 662025

6 hospitals in Zhengzhou for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineRheumatology & immunology
Papers it led26
  1. Carotid intima thickness and elasticity combined with MHR predicting the severity of coronary artery stenosis in patients with premature coronary artery disease.2025BMC cardiovascular disordersFree full text
  2. Impact of Insomnia on Myocardial Infarction Risk and Coronary Plaque Vulnerability: Insights From Mendelian Randomization and OCT Imaging.2025Clinical cardiologyFree full text
  3. Serum sST2, IL-33, and Hcy Expression in Older Adults Patients with Myocardial Infarction and Their Predictive Value for MACE.2025Clinical interventions in agingFree full text
  4. Elevated serum uric acid as an independent risk factor for multiple stent placement in non-hypertensive, non-diabetic patients with coronary artery disease: a retrospective cohort analysis.2025Clinical rheumatology
  5. Unveiling the role of risk factors and predictive models in acute type-a aortic dissection surgery: OI downregulation and its association with immune disorders.2025International journal of medical sciencesFree full text
  6. Relationship Between Aldehyde Dehydrogenase 2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries.2025Journal of cardiovascular pharmacology
  7. Insulin resistance and coronary inflammation in patients with coronary artery disease: a cross-sectional study.2024Cardiovascular diabetologyFree full text
  8. Diagnostic and prognostic value of serum Cys-C, retinol-binding protein, and ischemia-modified albumin in patients with coronary heart disease: A diagnostic accuracy study.2024MedicineFree full text
  9. Optical coherence tomography analysis of lesion characteristics and thrombus types in non ST-segment elevation myocardial infarction patients.2024The international journal of cardiovascular imagingFree full text
  10. Kinesiophobia and its associated factors in patients with coronary heart disease: a cross-sectional study based on latent feature analysis.2023BMJ openFree full text
  11. Triglyceride-glucose index as a marker of adverse cardiovascular prognosis in patients with coronary heart disease and hypertension.2023Cardiovascular diabetologyFree full text
  12. Safety and efficacy of enterprise stenting for symptomatic atherosclerotic severe posterior circulation stenosis.2023European journal of medical researchFree full text
  13. Validation of a predictive model for coronary artery disease in patients with diabetes.2023Journal of cardiovascular medicine (Hagerstown, Md.)Free full text
  14. Clinical characteristics and outcomes of Chinese patients with coronary heart disease and resistant hypertension.2023Journal of clinical hypertension (Greenwich, Conn.)Free full text
  15. The "L-Sandwich" Strategy for True Coronary Bifurcation Lesions: A Randomized Clinical Trial.2023Journal of interventional cardiologyRCTFree full text
  16. SPECT myocardial blood flow quantitation for the detection of angiographic stenoses with cardiac-dedicated CZT SPECT.2023Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
  17. GAS5/METTL14/ESR1 genetic variants are related to the susceptibility of coronary heart disease.2022Functional & integrative genomics
  18. Remote ischemic preconditioning can extend the tolerance to extended drug-coated balloon inflation time by reducing myocardial damage during percutaneous coronary intervention.2022International journal of cardiologyRCT
  19. Clinical and imaging characteristics of cardiac magnetic resonance presenting with myocardial infarction with non-obstructive coronary arteries in China.2022Journal of cardiothoracic surgeryFree full text
  20. Histone Deacetylase 1 Depletion Alleviates Coronary Heart Disease Via the MicroRNA-182-Mediated Transforming Growth Factor β/Smad Signaling Pathway.2022Journal of cardiovascular pharmacology
  21. Relationship between cognitive emotion regulation strategies and coronary heart disease: an empirical examination of heart rate variability and coronary stenosis.2022Psychology & health
  22. Prediction of all-cause mortality in coronary artery disease patients with atrial fibrillation based on machine learning models.2021BMC cardiovascular disordersFree full text
  23. Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies.2021BMC cardiovascular disordersFree full text
  24. Suppression of microRNA-323-3p restrains vascular endothelial cell apoptosis via promoting sirtuin-1 expression in coronary heart disease.2021Life sciences
  25. Analysis of Characteristics of Patients with Non-ST-Segment Elevation Myocardial Infarction by Cardiac Magnetic Resonance Imaging.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  26. Factors affecting in-stent restenosis after angioplasty with the Enterprise stent for intracranial atherosclerotic diseases.2021Scientific reportsFree full text
Chinese-language papers (not in the count)3
  1. [The relationship between variant angina pectoris syncope and coronary artery spastic targeted location, arrhythmia and coronary artery stenostic lesion].2025Zhonghua xin xue guan bing za zhi
  2. [Clinical efficacy evaluation of minimally invasive cardiac surgery coronary artery bypass grafting in patients with multivessel coronary artery disease].2022Zhonghua yi xue za zhi
  3. [Association of RAGE gene polymorphisms with MHR ratio and heart rate variability among patients with coronary heart disease].2021Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
All its trials on ClinicalTrials.gov, any status4
  1. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemNot yet recruitingNCT04995159Study siteN/AStart 2021-09
  2. Effect of Antithrombotic Treatment in Patients With Both Coronary Heart Disease and Atrial FibrillationStatus unknownNCT03051061Study siteStart 2017-02
  3. Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World SettingCompletedNCT02565615Study siteStart 2016-06
  4. Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery DiseaseStatus unknownNCT01418794Study sitePhase 4Start 2010-10

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 14 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.5%.

Papers led
14
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 4420232024: 2220242025: 222025

6 hospitals in Zhengzhou for congenital heart disease207 hospitals in China for congenital heart disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
    Phase
    Not given
    Started
    2025-12
    Posted
    Registry
    NCT07292896

    Age 18 years to 79 years (registered criteria)

    Led by First Hospital of China Medical University; 11 listed hospitals as study sitesBeijing, Changchun, Chengdu, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led14
  1. Identification of novel biallelic mutations in CFAP53 associated with fetal situs inversus totalis and literature review.2026Journal of applied genetics
  2. Remimazolam for successful sedation in children with left-to-right shunt congenital heart disease: An up-and-down sequential allocation trial.2025European journal of anaesthesiologyFree full text
  3. Unveiling the role of risk factors and predictive models in acute type-a aortic dissection surgery: OI downregulation and its association with immune disorders.2025International journal of medical sciencesFree full text
  4. Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome.2024EBioMedicineFree full text
  5. Identifying the critical windows of temperature extremes exposure and congenital heart diseases.2024International journal of biometeorology
  6. Alternating Early Afterdepolarizations Underlying Bradycardia-Dependent Macroscopic T Wave and Discordant Mechanical Alternans.2023Circulation. Arrhythmia and electrophysiology
  7. Trans-jugular transcutaneous closure of atrial septal defects with an adjustable curved sheath under echocardiography guidance.2023Echocardiography (Mount Kisco, N.Y.)
  8. Peratrial device closure of perimembranous ventricular septal defects via a small right subaxillary incision: Midterm results in patients <12 months of age.2023International journal of cardiology
  9. A novel mutation in PCD-associated gene DNAAF3 causes male infertility due to asthenozoospermia.2023Journal of cellular and molecular medicineFree full text
  10. Preoperative sedation in children with congenital heart disease: 50% and 95% effective doses, hemodynamic effects, and safety of intranasal dexmedetomidine.2022Journal of clinical anesthesia
  11. Different effects of maternal homocysteine concentration, MTHFR and MTRR genetic polymorphisms on the occurrence of fetal aneuploidy.2022Reproductive biomedicine online
  12. Exploration and validation of hub genes and pathways in the progression of hypoplastic left heart syndrome via weighted gene co-expression network analysis.2021BMC cardiovascular disordersFree full text
  13. Knockdown of Long Noncoding RNA SNHG14 Protects H9c2 Cells Against Hypoxia-induced Injury by Modulating miR-25-3p/KLF4 Axis in Vitro.2021Journal of cardiovascular pharmacology
  14. Asymmetric Occluder Occlusion of Outlet Ventricular Septal Defect Via a Subaxillary Approach.2021The Annals of thoracic surgery
Chinese-language papers (not in the count)3
  1. [Genetic analysis of primary ciliary dyskinesia caused by DNAH5 splicing site mutations].2025Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  2. [Early warning of low maternal unconjugated estriol level by prenatal screening for fetus with X-linked ichthyosis].2022Zhonghua fu chan ke za zhi
  3. [Effect and prognosis of new type of re-dilated stent in the treatment of pulmonary artery bifurcation stenosis].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional EchocardiographyNot yet recruitingNCT07292896Study siteStart 2025-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Scoliosis

脊柱侧弯

Led no English-language PubMed papers on scoliosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

2 hospitals in Zhengzhou for scoliosis107 hospitals in China for scoliosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery
    Phase
    Phase 4
    Started
    2026-04
    Posted
    Registry
    NCT07229495

    Age 10 years to 17 years (registered criteria)

    Led by Peking Union Medical College Hospital; 5 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Tegileridine for Postoperative Pain After Adolescent Scoliosis SurgeryRecruitingNCT07229495Study sitePhase 4Start 2026-04
  2. Degenerative Lumbar ScoliosisStatus unknownNCT05485636Study siteStart 2022-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

6 hospitals in Zhengzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Zhengzhou for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 5 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025

8 hospitals in Zhengzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Posted
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

  2. Recruiting
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07121413

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesChengdu, Guangzhou, Hangzhou, Hohhot, Nanchang, Nanjing, Shanghai, Tianjin, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led5
  1. Antidepressant intervention to possibly delay disease progression and frailty in elderly idiopathic pulmonary fibrosis patients: a clinical trial.2025Aging clinical and experimental researchFree full text
  2. Potential function exploration of lncRNAs in idiopathic pulmonary fibrosis: insights from whole transcriptome sequencing data analysis.2025Clinics (Sao Paulo, Brazil)Free full text
  3. Integrative Analysis of Endothelial Cell Senescence-Related Genes in Idiopathic Pulmonary Fibrosis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  4. Genetic association of telomere length, obesity and tobacoo smoking with idiopathic pulmonary fibrosis risk.2023BMC public healthFree full text
  5. Contribution of Adiponectin/Carnitine Palmityl Transferase 1A-Mediated Fatty Acid Metabolism during the Development of Idiopathic Pulmonary Fibrosis.2022Oxidative medicine and cellular longevityFree full text
Earlier papers (2016–2020)3
  1. Research Advances on DNA Methylation in Idiopathic Pulmonary Fibrosis.2020Advances in experimental medicine and biology
  2. Downregulation of microRNA‑30a in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis patients.2018Molecular medicine reports
  3. Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Uncertainties and Controversies.2018Respiration; international review of thoracic diseases
All its trials on ClinicalTrials.gov, any status5
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary FibrosisRecruitingNCT07121413Study sitePhase 2Start 2025-11
  3. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  4. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  5. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Zhengzhou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. Two new cases with the UBQLN2 gene mutation in Han Chinese.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Earlier papers (2016–2020)2
  1. Novel mutation in optineurin causing aggressive ALS+/-frontotemporal dementia.2019Annals of clinical and translational neurology
  2. A novel SETX gene mutation associated with Juvenile amyotrophic lateral sclerosis.2018Brain and behavior

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Zhengzhou for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Zhengzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led1
  1. Molecular Pathogenic Mechanisms of IgA Nephropathy Secondary to COVID-19 mRNA Vaccination.2024Kidney & blood pressure research
All its trials on ClinicalTrials.gov, any status4
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Zhengzhou for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution

2 hospitals in Zhengzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Posted
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Posted
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan'an, Zhengzhou

  3. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Posted
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Study sitePhase 2/Phase 3Start 2023-02
  3. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  4. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Zhengzhou for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Posted
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing CholangitisRecruitingNCT07387549Study sitePhase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 2 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 3.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 0020242025: 002025

3 hospitals in Zhengzhou for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led2
  1. Dystrophic Epidermolysis Bullosa Pruriginosa: Successfully Treated With Dupilumab.2023Dermatitis : contact, atopic, occupational, drug
  2. Haplotype-based non-invasive prenatal diagnosis of recessive dystrophic epidermolysis bullosa via targeted capture sequencing of maternal plasma.2023The Journal of dermatology
Chinese-language papers (not in the count)1
  1. [Variation of COL7A1 gene in dystrophic epidermolysis bullosa pruriginosa].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Earlier papers (2016–2020)1
  1. [Genetic analysis of a child with recessive dystrophic epidermolysis bullosa due to compound heterozygous variants of (COL7A1 gene].2020Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Zhengzhou for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in ChinaCompletedNCT06346899Study siteStart 2024-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 3 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 5.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 0020242025: 002025

2 hospitals in Zhengzhou for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

河南省人民医院

Henan Provincial People's Hospital

郑州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
People's Hospital of Zhengzhou University; Zhengzhou University People's Hospital; and Affiliated Provincial People's Hospital of Zhengzhou University; Heart Center of Henan Provincial People's Hospital; Henan Provincial People' Hospital; Affiliated People's Hospital of Zhengzhou University; Henan Provincial People's Hospital Affiliated to Zhengzhou University; and Henan Provincial People's Hospital

Suggest a correctionDownload the data